Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

David Ewing Duncan

A View from David Ewing Duncan

New UCSF Chancellor a Boost for Personalized Medicine?

Former Genentech president Susan Desmond-Hellmann is nominated to be the next UCSF chancellor.

  • May 5, 2009

When Roche bought Genentech last month, speculation was rife about where the newly enriched leadership of this biotech behemoth would end up. For president of product development Susan Desmond-Hellmann, it didn’t take long to settle the issue.

Last Friday, Mark Yudof, president of the University of California, announced that Desmond-Hellmann is his nominee for the chancellor of UC San Francisco–subject to approval by the UC Board of Regents. Her arrival could mean a substantial boost for personalized medicine–the tailoring of treatments and diagnostic tests according to an individual patient’s genes and physiology. She oversaw the development of Herceptin, the Genentech blockbuster to treat breast cancer that only works for patients who overexpress a gene called HER2. She also oversaw the development of the blockbusters Rituxin and Avastin.

Unfortunately, other examples of truly personalized medicine have been scarce in the drug industry, despite an explosion of research data produced by molecular biologists in recent years. Most of this data, however, has not been translated into either new drugs or diagnostics. Many reasons are given, including the complexity of the science and a research infrastructure that still values discovery more than the development and application of those discoveries.

Efforts are under way at the National Institutes of Health and at some universities to develop new and better methods to shift basic research in genetics, proteomics, and other fields into useful products and protocols, but no national leader has emerged to spearhead the effort.

Desmond-Hellmann has not yet revealed her plans or focus should she be approved as chancellor of UCSF, but she is uniquely poised to perhaps take on this role as a bridge between research and development.

Hopefully, she will keep the two in proper balance, remembering her first career as a full-time oncologist who joined pharma out of frustration at being able to do so little for her patients.

The latest Insider Conversation is live! Listen to the story behind the story.

Subscribe today
Already a Premium subscriber? Log in.
Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.